Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: A case study and review of the literature

Case Reports in Oncology

Volumn 4, Issue 1, 2011, Pages 55-59

  Delgado, M ^a   Perez Ruiz E ^a   Alcalde, J ^a   Perez D ^a   Villatoro, R ^a   Rueda, A ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Haemangiopericytoma; Platelet derived growth factor receptor; Sunitinib; Vascular endothelial growth factor receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE; SUNITINIB;

ADENOMA; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CASE REPORT; DISSEMINATED MENINGEAL HAEMANGIOPERICYTOMA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEMANGIOPERICYTOMA; HUMAN; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; MEDICAL HISTORY; MEDICAL LITERATURE; METASTASIS; NEUTROPENIA; PAROTID ADENOMA; PETECHIA; PRIORITY JOURNAL; RECURRENT CANCER; STEREOTACTIC BODY RADIATION THERAPY; THROMBOCYTOPENIA;

EID: 79957627733     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000324487     Document Type: Article

References (11)

1. Mena H, Ribus JL, Pezeshkpour GH, et al: Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 1991;22:84-91.
2. Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG: Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989;25:514-522. (Pubitemid 19236255)
3. Dufour H, Metellus P, Fuentes S, et al: Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 2001;48:756-762, discussion 762-763. (Pubitemid 32268084)
4. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG: Management of recurrent meningeal hemangiopericytoma. Cancer 1998;82:1915-1920. (Pubitemid 28208648)
5. Wong P, Yagoda A: Chemotherapy of malignant hemangiopericytoma. Cancer 1978;41:1256-1260. (Pubitemid 8330405)
6. Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010;22:351-355.
7. Dietzmann K, von Bossanyi P, Warich-Kirches M, et al: Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas. Pathol Res Pract 1997;193:503-510. (Pubitemid 27434461)
8. Kirn DH, Kramer A: Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 1996;88:764-765.
9. Mulamalla K, Truskinovsky A, Dudek A, et al: Rare case of hemangiopericytoma responds to sunitinib. Transl Res 2008;151:129-133.
10. Domont J, Massard C, Lassau N, et al: Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapse malignant hemangiopericytoma/solitary fibrous tumour. Invest New Drugs 2010;28:199-202.
11. Peters K, McLendon R, Morse M, et al: Treatment of recurrent intracranial hemangiopericytoma with SRCrelated tirosin kinase targeted therapy. A case report. Case Rep Oncol 2010;3:93-97.